Sign in
4

Changes in Ownership

PTC THERAPEUTICS, INC. Filed Acc 0001578852-26-000002

EXEC. VP AND CLO sold 2,266 shares at an average $75.55 ($171,192)

  • EXEC. VP AND CLO acquired 2,266 shares (option exercise)
  • EXEC. VP AND CLO acquired 17,000 shares (grant or award)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Boulding Mark Elliott · EXEC. VP AND CLO

Table I: Non-derivative

5 lines
Date Transaction Shares Price Value Owned after D/I
2026-01-02 Grant or award : show line 1 in the form 10b5-1 +17,000 120,901 D
2026-01-05 Exercise or conversion : show line 2 in the form 10b5-1 +2,266 $39.42 $89,326 123,167 D
2026-01-05 Sale : show line 3 in the form 10b5-1 −1,123 $74.92 $84,135 122,044 D
2026-01-05 Sale : show line 4 in the form 10b5-1 −1,035 $76.10 $78,764 121,009 D
2026-01-05 Sale : show line 5 in the form 10b5-1 −108 $76.79 $8,293 120,901 D
Open-market sales · 2,266 sh · avg $75.55 · $171,192

Table II: Derivative

2 lines
Date Transaction Shares Owned after D/I
2026-01-02 Grant or award : show line 6 in the form 10b5-1 Stock Option (Right to Buy) +42,500 42,500 D
2026-01-05 Exercise or conversion : show line 7 in the form 10b5-1 Stock Option (Right to Buy) −2,266 9,063 D
Loading xslF345X05/form4-01062026_050119.xml…